Synthelabo presents new 5-HT1A inverse agonist with antagonist and anxiolytic-like activity in vivo Nov. 11, 1998
LY-300164 protects against kainate-induced neurotoxicity in vitro in a stereoselective manner Nov. 11, 1998
Knoll develops potential new antipsychotic agent with advantages over available therapies Nov. 10, 1998
RSS